EUVIMEDObjevte EUVIMED
Open access

Design, Synthesis, and Structure–Activity Relationship Studies of Novel 3CL pro Inhibitors

Yixuan Feng, Feng Wang, Donglan Liu, Qiqi Yan, Leyuan Kang, Wenhao Zhao iD, Shixin Jin, Shuxiang Huang, Jincun Zhao, Ping Tian iD, Dingding Gao iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.70459 ↗

At a glance

Journal article in ChemMedChem, 2026. Written by Yixuan Feng and 10 co-authors. Institution: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Innovation Research Institute of Traditio…. Major MEDLINE topics: Antiviral Agents, Drug Design, SARS-CoV-2, Coronavirus 3C Proteases. 27 references. The full text is freely available in PubMed Central. Funded by: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Shanghai PuJiang Programme.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The SARS‐CoV‐2 3C‐like protease (3CL pro ) is an essential enzyme for coronavirus replication and remains an attractive antiviral target due to its high sequence conservation among coronaviruses. Based on a previously identified catechol‐containing covalent 3CL pro inhibitor ( P1‐E11 ), structural optimization was carried out using a linker‐replacement strategy to systematically modify the central linker moiety. Two series comprising 20 analogues were designed, synthesized, and evaluated for enzymatic and antiviral activities. Among them, compound B2 , featuring a direct amide linkage between the catechol warhead and the 4‐(trifluoromethoxy)phenyl group, exhibited improved enzymatic inhibition (IC 50 = 0.83 ± 0.06 μM) and favorable covalent inhibition kinetics ( k inact / K i = 380.01 M −1 s −1 ). In cell‐based assays (A549‐hACE2‐TMPRSS2), B2 showed antiviral activity (EC 50 = 15.03 ± 1.13 μM) with acceptable cytotoxicity (CC 50 = 79.87 ± 6.85 μM). Structure–activity relationship analysis revealed that sulfur‐containing linkers enhanced antiviral potency in certain cases but were associated with increased cytotoxicity. Collectively, this study expands the structural framework of covalent 3CL pro inhibitors and offers a rational strategy for their further optimization.

Subjects

MeSH terms (MEDLINE)

Antiviral AgentsDrug DesignSARS-CoV-2Coronavirus 3C ProteasesCysteine Proteinase InhibitorsStructure-Activity RelationshipHumansMolecular StructureA549 CellsMolecular Docking SimulationDose-Response Relationship, Drug

Author keywords

SARS‐CoV‐2 3CLproantiviral activitiescatechol derivativescovalent inhibitors

Substances

Antiviral AgentsCoronavirus 3C Proteases3C-like proteinase, SARS-CoV-2Cysteine Proteinase Inhibitors

Authors and institutions

  • State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medic…
  • Phase I Clinical Trials Center, Shenzhen People's Hospital (The First Affiliated Hospital Southern University of Science and Technology; The Second Clinical Medical College Jinan University), Shenzhen, China.
  • State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou…
  • Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, Guangdong, China.
  • Health and Quarantine Laboratory, Guangzhou Customs District Technology Center, Guangzhou, China.

ORCID profiles: Wenhao Zhao, Ping Tian, Dingding Gao

Funding

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality
  • Shanghai PuJiang Programme
  • Shanghai Leading Talent Program of Eastern Talent
  • State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine
  • Shanghai Municipal Health Commission
  • Expenditure Budget Program of Shanghai University of Traditional Chinese Medicine
  • Shanghai Frontiers Science Center for Traditional Chinese Medicine Chemical Biology, and Guangdong High-Level Talent Program

Cite

APA

Feng, Y., Wang, F., Liu, D., Yan, Q., Kang, L., Zhao, W., Jin, S., Huang, S., Zhao, J., Tian, P., & Gao, D. (2026). Design, Synthesis, and Structure–Activity Relationship Studies of Novel 3CL pro Inhibitors. ChemMedChem. https://doi.org/10.1002/cmdc.70459

Vancouver

Feng Y, Wang F, Liu D, Yan Q, Kang L, Zhao W, et al. Design, Synthesis, and Structure–Activity Relationship Studies of Novel 3CL pro Inhibitors. ChemMedChem. 2026. doi:10.1002/cmdc.70459

BibTeX
@article{Feng2026,
  author = {Feng, Yixuan and Wang, Feng and Liu, Donglan and Yan, Qiqi and Kang, Leyuan and Zhao, Wenhao and Jin, Shixin and Huang, Shuxiang and Zhao, Jincun and Tian, Ping and Gao, Dingding},
  title = {Design, Synthesis, and Structure–Activity Relationship Studies of Novel 3CL pro Inhibitors},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.70459}
}
Start for free →